-23.7%
MARA vs MRNA
+485.7%
-509.5%
-70.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.8% | +5.4% | -0.6% | +4.4% |
| 7D | +5.9% | -1.1% | +7.0% | +6.0% |
| 30D | +24.3% | +126.1% | -101.8% | +8.9% |
| 3M | -12.0% | +190.0% | -202.0% | -30.7% |
| 6M | +40.1% | +157.2% | -117.1% | +14.3% |
| YTD | +33.4% | +388.2% | -354.8% | -10.9% |
| 1Y | -23.7% | +467.0% | -490.8% | -50.1% |
| All | -23.7% | +485.7% | -509.5% | -50.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling